CD86 and neoplasm: More importantly, as a subtype of professional antigen‐presenting cells (APCs), M2‐like macrophages usually display weak antigen presentation capability, while M1‐like macrophages up‐regulate major histocompatibility complex class II (MHC‐II) molecules and positive‐costimulatory molecules CD40, CD80, and CD86 to exhibit potent antigen presentation capability.[6, 12] Therefore, developing strategies to decrease the number of M2‐like macrophages or promote M2‐to‐M1 repolarization holds great promise to bridge innate and adaptive immunity for enhancing tumor immunotherapies.